nomelcitinib

Nomelcitinib (D-2570) is an orally bioavailable, highly selective small molecule inhibitor of **Tyrosine Kinase 2 (TYK2)**, developed by **Beijing Delifore Pharmaceutical Technology** (also known as **InventisBio**). By targeting the allosteric pseudokinase (JH2) domain of TYK2, nomelcitinib achieves high selectivity over other Janus kinases (JAK1, JAK2, and JAK3), thereby minimizing off-target effects associated with broad JAK inhibition. It functions by blocking the signaling pathways of key cytokines, including interleukin-23 (IL-23), interleukin-12 (IL-12), and Type I interferons, which are central to the pathogenesis of various autoimmune and inflammatory diseases. Nomelcitinib is currently in late-stage clinical development, with **Phase 3** trials for **plaque psoriasis** and **Phase 2** trials for **ulcerative colitis**, **systemic lupus erythematosus (SLE)**, and **psoriatic arthritis**.

Other names

D-2570D2570D 2570